Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus A Infections: Likelihood of Approval
Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus A Infections. According to...
Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus B Infections: Likelihood of Approval
Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus B Infections. According to...
Influenza (quadrivalent) vaccine by Vaxxas for Influenzavirus A Infections: Likelihood of Approval
Influenza (quadrivalent) vaccine is under clinical development by Vaxxas and currently in Phase I for Influenzavirus A Infections. According to...
Influenza (quadrivalent) vaccine by Vaxxas for Influenzavirus B Infections: Likelihood of Approval
Influenza (quadrivalent) vaccine is under clinical development by Vaxxas and currently in Phase I for Influenzavirus B Infections. According to...
Influenza (quadrivalent) vaccine by Vaxxas for Seasonal Influenza: Likelihood of Approval
Influenza (quadrivalent) vaccine is under clinical development by Vaxxas and currently in Phase I for Seasonal Influenza. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Influenza (quadrivalent) vaccine?
Influenza (quadrivalent) vaccine is a mrna vaccine commercialized by Pfizer, with a leading Phase III program in Influenzavirus B Infections....